TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00191698
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01421459
Drug: LY2963016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT01421459
Drug: OAMs
Normalized name: ALCOHOL 0.7 L in 1 L TOPICAL LIQUID [MG FoamSan 70]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00002985
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006377
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03635879
Drug: AC-1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
Study: NCT04355832
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of normal saline solution that will mimic Glucagon-like peptide-1
Study: NCT04414930
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive placebo po 1 hour prior to each training.
Study: NCT03377322
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - one capsule a day for four weeks
Study: NCT04991155
Drug: BIA 5-1058
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.
Study: NCT00740142
Drug: L-ornithine-L-aspartate and lactulose
Normalized name: ornithine, (L)-isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
Study: NCT04056442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive Oil Solution, 5%
Study: NCT02607891
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT02607891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT01165255
Drug: 3. Exposure to other antidepressants during the first trimester comparison cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to other antidepressants during first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate dispensing of other antidepressants. Infants were classified according to maternal exposure to other antidepressants during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women who were exposed only to one type of an antidepressant (other antidepressant monotherapy), or more than one type of an antidepressant (other antidepressant mono or polytherapy) during the first trimester. A woman was considered exposed if there is at least one dispensing of another antidepressant during the first trimester of pregnancy.
Study: NCT00333866
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03762109
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive pill
Study: NCT02510274
Drug: ASP3325
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00050011
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
Study: NCT04507269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline given by subcutaneous injection
Study: NCT00323518
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously as 100mL single dose over 15 minutes on day 1
Study: NCT03615768
Drug: Clindamycin Gel
Normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
Study: NCT03378635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for dasiglucagon
Study: NCT00648713
Drug: Lamisil® Tablets 250 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg, single dose fed
Study: NCT00027300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, IV infusion, every 4 weeks, for up to 116 weeks.
Study: NCT03726879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to atezolizumab will be administered as per the schedule specified in the respective arm.
Study: NCT03726879
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered as per the schedule specified in the respective arm.
Study: NCT03726879
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as per the schedule specified in the respective arm.
Study: NCT02766478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo pill will be taken orally for 12 weeks.
Study: NCT04451330
Drug: Doxycycline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline hyclate delayed release 120 mg placebo tablets was administered orally for 12 weeks.
Study: NCT02173912
Drug: CJ-30059 (Test)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between.
Study: NCT03832582
Drug: Annexin
Normalized name: Annexin
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
Study: NCT01341262
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * INDUCTION THERAPY: 4 mg i.v. once a cycle for 4 cycles (30 days each)~* AFTER PBSC COLLECTION: 4 mg i.v. once (the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 4 mg i.v. once a cycle (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)
Study: NCT01341262
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 7 g/sqm + G-CSF 5 mcg/Kg from the day +6 for stem cell mobilisation
Study: NCT03342950
Drug: Topical Solution
Normalized name: Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Solution of Clonidine (0.01%) + Pentoxifylline (5%) in anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
Study: NCT03342950
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Solution of anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
Study: NCT03129074
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: from Day 1 to Day 14 followed by 7-day of rest period, every 21 days.
Study: NCT02410980
Drug: Tretinoin cream 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of the skin change
Study: NCT04075331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution for subcutaneous injection
Study: NCT03208179
Drug: dihydroartemisinin-piperaquine plus azithromycin
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)
Study: NCT00530257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sugar pill)
Study: NCT00212030
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control
Study: NCT01733407
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg/kg/d divided TID for year 1 only.
Study: NCT03629717
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200mg daily
Study: NCT02198248
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.~High-dose group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule.
Study: NCT04482803
Drug: Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before NST, one of the clinically assesed positive lymph nodes will be subjected to ultrasound-guided CNB or FNA, and a locating clip (Ultraclip, BARD) will be placed. Meanwhile, a small amount of Kanarine (carbon nanoparticles suspension injection, 0.5ml:25mg, H20073246) will be injected into or around the cortex of the locating lymph node and other clinically assessed positive lymph nodes. Preoperative FNA will be performed again for locating clip labelled node.
Study: NCT01881958
Drug: DiaPep277®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03083080
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
Study: NCT02667561
Drug: Testosterone gel 1% 2.2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of 220 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Study: NCT02667561
Drug: Testosterone gel 1% 4.4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of 440 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Study: NCT02667561
Drug: Testosterone gel 1% 8.8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of 880 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Study: NCT02667561
Drug: Placebo of Testosterone Gel 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of approximately 550 mg of Placebo of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Study: NCT05008250
Drug: Tongmai Yangxin Pill (TMYXP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMYXP is a Chinese patent medicine developed by many years of clinical practice experience. The ingredients of TMYXP are Radix Rehmanniae, Caulis Spatholobi, Polygonum Multiflorum, Colla Corii Asini, Ophiopogonis, Tortoise Shell (vinegar), Radix Codonopsis, Cassia Twig, Jujube, Schisandra Fruit, and Licorice Root. It has the effect of invigorating Qi, nourishing Yin, dredging the pulse, and relieving pain. It is used in treatment of Qi and Yin deficiency syndromes caused by coronary heart disease, angina pectoris, and arrhythmia.~Metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.
Study: NCT05008250
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: simulated pills
Study: NCT01526616
Drug: Metformin plus Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
Study: NCT04347239
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos
Study: NCT03945396
Drug: Homeopathic Medication
Normalized name: homeopathic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: A homeopathic mineral medicine, form of impure calcium carbonate, CaCO3, which can be found in nature in different niches, from limestone to eggshells.
Study: NCT04359329
Drug: Estradiol patch
Normalized name: Estradiol Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin
Study: NCT03945396
Drug: Homeopathic placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 30 ml bottle of 30% alcohol-distilled water.
Study: NCT00412763
Drug: Silymarin (Silybum marianum)
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00616681
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00403793
Drug: etonogestrel with testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
Study: NCT00403793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 or 44 weeks with placebo implant and placebo injections
Study: NCT01119885
Drug: fentanyl matrix
Normalized name: FentaNYL Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee osteoarthritis, starting with 12mcg/h (flexible dose)
Study: NCT01119885
Drug: fentanyl matrix
Normalized name: FentaNYL Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hip osteoarthritis, starting with 12mcg/h (flexible dose)
Study: NCT03330769
Drug: New course of treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of new course of NSAIDs (monotherapy), steroid intra-articular injections (monotherapy), conventional DMARDs, biologic DMARDs, including switches or dose augmentations, indicated by the treating rheumatologist according to usual clinical practice.
Study: NCT00388271
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment
Study: NCT04265781
Drug: BAY1817080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three different doses over the course of study
Study: NCT04265781
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo to BAY1817080
Study: NCT02060604
Drug: Ketorolac + Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 monthly ranibizumab, then as needed Ketorolac TID
Study: NCT00128778
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01326689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03220633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01110512
Drug: Flavonid
Normalized name: flavodic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day.
Study: NCT01110512
Drug: Daflon
Normalized name: Daflonex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day
Study: NCT01601561
Drug: Regular human insulin injection
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.~Humulin R 5 mU/kg/min and a variable infusion of glucose.
Study: NCT03574363
Drug: KBP-5074 0.25 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, QD, 84 days
Study: NCT03574363
Drug: KBP-5074 0.5 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, QD, 84 days
Study: NCT04319900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.
Study: NCT02383810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00398879
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks
Study: NCT00955526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tablets once daily for 12 weeks
Study: NCT01464606
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids
Study: NCT01464606
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)
Study: NCT04567433
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone compared to Placebo
Study: NCT03021265
Drug: T80/A5/H12.5 FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug
Study: NCT00541034
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05467436
Drug: Local anesthetics, IV sedation drugs and analgesics.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized prescription for local anesthetics, IV sedation drugs and analgesics, based on pharmacogenomic assesment, social, dietary and medication history
Study: NCT03163550
Drug: ACHN-383
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose
Study: NCT03163550
Drug: ACHN-789
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose
Study: NCT03163550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose
Study: NCT05699720
Drug: Nebulized Magnesium Sulphate
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A received 250mg of MgSO4 /dose given through nebulizer four times a day, while group B did not. The groups will be followed for five days to see the results in terms of in-hospital outcome, whether the patient is discharged after fulfilling the set criteria or needing assisted ventilation.
Study: NCT01656902
Drug: NOVOCART® 3D plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-Step intervention: 1) cartilage cells are collected from the patient during arthroscopy 2) collected cartilage cells are cultivated in a sterile environment, seeded in an organic matrix scaffold and implanted into the defect location (knee, femur)
Study: NCT00665847
Drug: Optimized background regimen (OBR)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir \[LPV\], darunavir \[DRV\], atazanavir \[ATV\] or saquinavir \[SQV\]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N\[t\]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
Study: NCT04229615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03965533
Drug: GSK2831781
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.
Study: NCT03965533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.
Study: NCT04234321
Drug: Kangfuxin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
Study: NCT04234321
Drug: 0.9% Normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal saline,20ml / 100cm2 / time,three times a day.
Study: NCT01590342
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac 75 mg, two doses
Study: NCT01590342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, two doses
Study: NCT00975481
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet or capsule; placebo, single dose
Study: NCT00324324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
Study: NCT03447990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Ascending Dose and Multiple Ascending Dose of placebo
Study: NCT00412022
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg every 6 months
Study: NCT02022098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo solution
Study: NCT00616655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo total daily dose 0.9 mg
Study: NCT01863225
Drug: RVX000222
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
Study: NCT01863225
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg daily, 28-42 days
Study: NCT01863225
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg daily, 28-42 days
Study: NCT01551693
Drug: STA-9090
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00830336
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Suspension
Study: NCT00830336
Drug: Zithromax®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Suspension
Study: NCT03984604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a vehicle oil will match CHI-921
Study: NCT01920113
Drug: Dexmedetomidine - remifentanil group
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01920113
Drug: Propofol - remifentanil group
Approvals — FDA: no, EMA: no, PMDA: no